The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

DetermaIO identified patients who benefited from neoadjuvant immunotherapy resulting in improved pCR rate, independently of PDL1.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2024-09-23
DOI
https://doi.org/10.1158/1078-0432.ccr-24-0149
Citations
17
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
4.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

Douglas Teller Ross, Brock L. Schweitzer, Begoña Bermejo, Lajos Pusztai et al.
17 citations
Clinical Cancer Research
Cancer Immunotherapy and Biomarkers
4.80
article

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

Douglas Teller Ross, Brock L. Schweitzer, Begoña Bermejo, Lajos Pusztai, C. Zamagni, Balázs Győrffy, Chiun‐Sheng Huang, Barbara Galbardi, Robert S. Seitz, Richard Greil, Maurizio Callari, Stefania Russo, Daniel Egle, Giampaolo Bianchini, Tyler J. Nielsen, Marco Colleoni, Marc Thill, Luca Gianni, Pinuccia Valagussa, Matteo Dugo, Владимир Федорович Семиглазов, Lucia Del Mastro, Catherine M. Kelly, Eva Ciruelos, Gabriella Mariani, Giuseppe Viale, Antonio Antón, Olivia Blasi
article en
17 citations

Abstract

DetermaIO identified patients who benefited from neoadjuvant immunotherapy resulting in improved pCR rate, independently of PDL1.

Clinical Cancer ResearchVol. 30(21)
Semmelweis University (HU), Innsbruck Medical University (AT), Vita-Salute San Raffaele University (IT), Paracelsus Medical University (AT), Yale Cancer Center (US), Health University of Applied Sciences Tyrol (AT), BrustGesundheitZentrum Tirol (AT), Hospital Clínico Universitario de Valencia (ES), Fondazione Michelangelo (IT), Azienda Unità Sanitaria Locale di Ferrara (IT), Hospital Universitario 12 De Octubre (ES), Cancer Trials Ireland (IE), Hospital Universitario Miguel Servet (ES), Institute of Oncology NN Petrov (RU), Azienda USL di Bologna (IT), Ospedale Santa Maria della Misericordia di Udine (IT), National Taiwan University Hospital (TW), IRCCS Ospedale San Raffaele (IT), Ospedale Policlinico San Martino (IT), Agaplesion Markus Hospital (DE), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), INCLIVA Health Research Institute (ES), European Institute of Oncology (IT), University of Pecs (HU), HUN-REN Research Centre for Natural Sciences (HU), Incyte (United States) (US)
Breast Cancer Research Foundation, Bristol-Myers Squibb, Celgene, F. Hoffmann-La Roche, Associazione Italiana per la Ricerca sul Cancro
Openalex Percentile: Top 4%
Cancer Immunotherapy and Biomarkers
4.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.